Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.74 -4.33%
EPS Growth %: -138.7%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
SUNB, CULP, KFY, More
EPS Growth %: -138.7%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Korn Ferry (KFY) Tops Q1 EPS by 7c, Beats on Revenue; Offers Q2 EPS Guidance
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
